We are developing new cell-based regenerative therapies.
We use adult and induced pluripotent stem cells (iPSC), regenerative factors (human platelet lysate, hPL) and extracellular vesicles (EV) for effective regenerative cell-based therapy approaches.

Research focus areas

Horizon EU
Heal
2022 - 2026
Broken Hearts
Deep Immune-Phenotyping of HLA-homozygous iPS-Cardiomyocytes

Horizon EU
Proto
2023 - 2027
Broken Bones
Mode of action & molecular mechanism of regenerative cell therapy in osteoarthritis

WISS25
GoodFibration
2024 - 2027
Scar-free Regeneration
Advancing scalable iPSC heart therapies for treating heart failure.

COST EU
Haplo.iPS
2022 - 2026
Universal Transplants
Developing HLA-homozygous hiPSC therapies, fostering collaboration, innovation, and inclusivity.





